Pawxy Tablets contain Cefpodoxime Proxetil, a broad-spectrum antibiotic with an ideal pharmacokinetic profile for oral use. Designed as a time-dependent cephalosporin, it offers a long half-life, allowing for once-daily dosing. This improves compliance in dogs, making treatment easier and more effective, while ensuring better clinical outcomes. Pawxy is suitable for both dogs and cats and is commonly prescribed for bacterial infections affecting the skin, respiratory tract, and during surgical interventions.
Composition: Cefpodoxime Proxetil
Class: Broad Spectrum Antibiotic
Indications/Uses:
-
Skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus intermedius, Staphylococcus aureus, Streptococcus canis (Group G, Beta-hemolytic), Escherichia coli, Pasteurella multocida, and Proteus mirabilis
-
Respiratory tract infections
-
Surgical interventions
Directions for Use:
Administer as recommended by the veterinarian. Suitable for dogs and cats.
Key Features and Benefits:
-
Contains Cefpodoxime Proxetil, a proven broad-spectrum antibiotic
-
Effective for skin infections, respiratory tract infections, and post-surgical use
-
Long half-life supports once-daily dosing for easier administration
-
Improves treatment compliance and clinical outcomes in dogs
-
Veterinary-recommended formulation suitable for both dogs and cats
Disclosure:
A licensed vendor partner will deliver this medicine to you. Once the pharmacy accepts your order, the details of the pharmacy will be shared. Acceptance of your order depends on the validity of your doctor’s prescription and the availability of the medicine.
Disclaimer:
Our sole intention is to ensure consumers get accurate, expert-reviewed, and trustworthy information. This content should not be used as a substitute for professional medical advice. It may not cover every aspect of health conditions, lab tests, medicines, side effects, interactions, or warnings. Always consult your veterinarian for guidance specific to your pet’s health.

Reviews
There are no reviews yet.